Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 130

1.

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

Harris SC, Cipriano A, Colucci SV, Kapil RP, Geoffroy P, Hopyan T, Levy-Cooperman N.

Pain Med. 2015 Dec 14. pii: pnv004. [Epub ahead of print]

PMID:
26814240
2.

Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties.

Kapil RP, Cipriano A, Wen W, Yu Lynch S, He E, Colucci SV, Harris SC.

Clin Ther. 2015 Dec 31. pii: S0149-2918(15)01319-3. doi: 10.1016/j.clinthera.2015.12.003. [Epub ahead of print]

3.

Effects of Paroxetine,a CYP2D6 Inhibitor, on the Pharmacokinetic Properties of Hydrocodone After Coadministration With a Single-entity,Once-daily, Extended-release HydrocodoneTablet.

Kapil RP, Friedman K, Cipriano A, Michels G, Shet M, Mondal S, Harris SC.

Clin Ther. 2016 Jan 1;38(1):228-9. doi: 10.1016/j.clinthera.2015.10.024. Epub 2015 Nov 23. No abstract available.

PMID:
26615894
4.

Levonorgestrel Intrauterine Device Use in Overweight and Obese Women.

Saito-Tom LY, Soon RA, Harris SC, Salcedo J, Kaneshiro BE.

Hawaii J Med Public Health. 2015 Nov;74(11):369-74.

5.

Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.

Kapil RP, Friedman K, Cipriano A, Michels G, Shet M, Mondal SA, Harris SC.

Clin Ther. 2015 Oct 1;37(10):2286-96. doi: 10.1016/j.clinthera.2015.08.007. Epub 2015 Sep 6.

6.

SunSmart: evaluation of a pilot school-based sun protection intervention in Hispanic early adolescents.

Miller KA, Langholz BM, Ly T, Harris SC, Richardson JL, Peng DH, Cockburn MG.

Health Educ Res. 2015 Jun;30(3):371-9. doi: 10.1093/her/cyv011. Epub 2015 Mar 22.

PMID:
25801103
7.

Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects.

Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Harris SC, Kapil RP.

Drugs Aging. 2014 Oct;31(10):731-6. doi: 10.1007/s40266-014-0211-3.

PMID:
25246162
8.

Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users.

Colucci SV, Perrino PJ, Shram M, Bartlett C, Wang Y, Harris SC.

Clin Drug Investig. 2014 Jun;34(6):421-9. doi: 10.1007/s40261-014-0192-3.

9.

A single center's experience with noninvasive prenatal testing.

Beamon CJ, Hardisty EE, Harris SC, Vora NL.

Genet Med. 2014 Sep;16(9):681-7. doi: 10.1038/gim.2014.20. Epub 2014 Mar 27.

PMID:
24675675
10.

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.

Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM.

J Clin Pharmacol. 2014 Apr;54(4):468-77. doi: 10.1002/jcph.235. Epub 2013 Dec 11.

11.

Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration.

Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Moline ML, Harris SC, Kapil RP.

J Clin Pharmacol. 2014 Mar;54(3):282-90. doi: 10.1002/jcph.220. Epub 2013 Nov 27.

PMID:
24203450
12.

Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets.

Greenblatt DJ, Harmatz JS, Singh NN, Roth T, Harris SC, Kapil RP.

J Clin Pharmacol. 2013 Nov;53(11):1194-8. doi: 10.1002/jcph.159. Epub 2013 Sep 6.

PMID:
23939537
13.

EADB: an estrogenic activity database for assessing potential endocrine activity.

Shen J, Xu L, Fang H, Richard AM, Bray JD, Judson RS, Zhou G, Colatsky TJ, Aungst JL, Teng C, Harris SC, Ge W, Dai SY, Su Z, Jacobs AC, Harrouk W, Perkins R, Tong W, Hong H.

Toxicol Sci. 2013 Oct;135(2):277-91. doi: 10.1093/toxsci/kft164. Epub 2013 Jul 28.

14.

Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.

Sellers EM, Perrino PJ, Colucci SV, Harris SC.

J Psychopharmacol. 2013 Sep;27(9):808-16. doi: 10.1177/0269881113493364. Epub 2013 Jun 19.

PMID:
23784739
15.
16.

Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults.

Greenblatt DJ, Harmatz JS, Roth T, Singh NN, Moline ML, Harris SC, Kapil RP.

Clin Ther. 2013 May;35(5):604-11. doi: 10.1016/j.clinthera.2013.03.007. Epub 2013 Mar 28. Erratum in: Clin Ther. 2013 Jun;35(6):900.

PMID:
23541711
18.

SNPTrack™ : an integrated bioinformatics system for genetic association studies.

Xu J, Kelly R, Zhou G, Turner SA, Ding D, Harris SC, Hong H, Fang H, Tong W.

Hum Genomics. 2012 Jul 5;6:5. doi: 10.1186/1479-7364-6-5.

19.

Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.

Kapil RP, Cipriano A, Friedman K, Michels G, Shet MS, Colucci SV, Apseloff G, Kitzmiller J, Harris SC.

J Pain Symptom Manage. 2013 Jul;46(1):65-75. doi: 10.1016/j.jpainsymman.2012.06.014. Epub 2012 Sep 29.

PMID:
23026548
20.

Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.

Kapil RP, Cipriano A, Michels GH, Perrino P, O'Keefe SA, Shet MS, Colucci SV, Noveck RJ, Harris SC.

Clin Drug Investig. 2012 Sep 1;32(9):583-92. doi: 10.2165/11633060-000000000-00000.

PMID:
22845044
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk